What is cancer immunotherapy? How does immunotherapy work to control cancer? Should I consider participating in a cancer immunotherapy clinical trial?
In response to patients’ questions like these, Society for Immunotherapy of Cancer (SITC) just released an animated video explaining the basics of immuno-oncology, and showing how immunotherapy clinical trials are providing new hope for many non-small cell lung cancer (NSCLC) patients.
Cancer immunotherapy is a promising treatment option that harnesses the power of the immune system to recognize and attack cancer cells. Immunotherapy drugs have already received FDA approval for treating specific tumor types such as melanoma, prostate cancer and renal cell carcinoma, and scientists are using immunotherapies against several other types of cancer in clinical trials across the country. One of these diseases is non-small cell lung cancer (NSCLC), the type of cancer accounting for 85%-90% of lung cancer cases in the United States. Scientists have reported some positive results for immunotherapy treatments in NSCLC clinical trials, currently the only avenue for NSCLC patients to receive these drugs.
SITC created the engaging video, Non-small Cell Lung Cancer Immunotherapy: A New Hope™, in response to the growing demand for patient-centered educational resources about cancer immunotherapy treatments. This video offers unbiased, easy to understand explanations of how cancer immunotherapy works, as well as information about clinical trials for patients with NSCLC. The video was produced in collaboration with leading cancer care and support organizations including Cancer Support Community, LUNGevity, Lung Cancer Alliance, Bonnie J. Addario Lung Cancer Foundation, and Association of Community Cancer Centers, and offers hope by empowering patients to make informed treatment decisions that are best for them and their families.
Throughout the planning, writing, and editing stages of video production, SITC consulted with a range of stakeholders including an expert task force of three lung cancer immunotherapists, and two focus groups representing clinical oncologists, nurses, patients, social workers, and patient advocates. The resulting video offers a balanced view of NSCLC immunotherapy options as it equips viewers with the knowledge base they need to ask questions about participating in a clinical trial.
Since the launch of the video, SITC and our partnering organizations have witnessed a very positive response, and we are asking for YOUR help in spreading the message of hope for patients with NSCLC. Please pass the video along to your friends and family, and share the video on your social media networks! Together we can empower patients, raise awareness of promising immunotherapy treatments and promote innovations in cancer immunotherapy research.